Saturn V Capital Management Lp

Institutional manager — quarterly 13F holdings, Q ending 2026-03-31

Reported value
$552.2M
Q ending 2026-03-31
Prior quarter
$544.9M
Q ending 2025-12-31
Change
+1.3% QoQ · +178.7% YoY
Positions
21
reported holdings

Largest positions

All 21 reported positions, Q ending 2026-03-31. A manager can hold shares, calls and puts on the same security at once — such positions are listed as separate rows. Type: Shares = common stock, Put/Call = option positions (valued at the underlying), Principal = debt. Tickers link to stock pages where covered.
HoldingTickerTypeValueShares
Alumis IncALMSShares$70.5M3.2M
Amylyx Pharmaceuticals IncAMLXShares$60.5M4.3M
Abivax SaABVXShares$60.4M543K
Vaxcyte IncPCVXShares$47.9M825K
Pharvaris N VShares$33.9M1.2M
Immix Biopharma IncIMMXShares$33.6M3.7M
Celcuity IncCELCShares$32.2M282K
Jazz Pharmaceuticals PlcShares$30.8M163K
Disc Medicine IncIRONShares$28.8M450K
X4 Pharmaceuticals IncXFORShares$26.7M6.5M
Cogent Biosciences IncCOGTShares$24.1M627K
Monopar Therapeutics IncMNPRShares$18.9M346K
Dyne Therapeutics IncDYNShares$17.5M967K
Invivyd IncIVVDShares$14.2M10.9M
Candel Therapeutics IncCADLShares$14.2M2.9M
Oculis Holding AgShares$13.7M517K
Ovid Therapeutics IncOVIDShares$9.2M4.2M
Inhibikase Therapeutics IncIKTShares$6.5M3.9M
Zura Bio LtdShares$4.4M740K
Alto Neuroscience IncANROShares$2.0M89K
Satellos Bioscience IncMSLEShares$2.0M350K

Values as reported in public regulatory filings (USD); holdings are reported quarterly, up to 45 days after quarter end, and may contain reporting errors. Nothing here is investment advice.